Actuate Therapeutics presented new data from its Phase 2 trial at ASCO GI 2026, showing extended overall survival benefit with elraglusib plus chemotherapy for metastatic pancreatic cancer.
The study demonstrated a 38% reduction in the risk of death with the elraglusib combination compared to chemotherapy alone, with durable survival beyond 24 months.
The results suggest that adding elraglusib to standard chemotherapy may improve survival outcomes in metastatic pancreatic cancer patients.
Improved Overall Survival
Elraglusib combination showed a statistically significant improvement in overall survival compared to chemotherapy alone.
Long-Term Benefit
Patients on elraglusib treatment exhibited increased durable survival beyond 24 months, a critical milestone in metastatic pancreatic cancer.
Safety Profile
The safety and tolerability profile of elraglusib was consistent with previous data, indicating no new safety concerns.
Genomic Biomarkers
Identified potential biomarkers in the elraglusib group that could predict overall survival and guide future drug combinations.
Immunological Response
Combination therapy with elraglusib/GnP showed an increase in immune response markers, suggesting enhanced anti-tumor activity.
- The results indicate a significant advancement in treating metastatic pancreatic cancer, a disease with limited effective treatment options.
- Elraglusib in combination with standard chemotherapy has the potential to improve survival outcomes and address the high unmet medical need in metastatic pancreatic cancer.
- The findings from the Phase 2 study underscore the promise of elraglusib/GnP therapy in extending the overall survival of patients with this challenging cancer.
Actuate Therapeutics' Phase 2 trial data for elraglusib in metastatic pancreatic cancer presents a compelling case for improved survival outcomes and a manageable safety profile. The results highlight the potential of elraglusib combination therapy in addressing the high unmet medical need in treating this difficult-to-treat cancer.